AGP Executive Report
Last update: 4 hours agoVaccine & Pharma Finance: Valneva reported €64.0M in first-half 2026 product sales, reaffirmed full-year guidance of €135–150M, and said it has €121.5M cash at end June, alongside a restructuring program expected to improve results later this year; the company also flagged regulatory decisions for its Lyme disease vaccine candidate as due within the next 12 months. Climate & Public Health: A new look at urban heat islands warns that hot-humid tropical cities can’t always afford fixes like shade, green roofs, lighter surfaces, and better cooling infrastructure—especially as El Niño strengthens and could push temperatures to dangerous levels for vulnerable residents. Drug Policy & Community Health: Mauritius’ ongoing drug crisis is back in the spotlight after a high-profile arrest tied to alleged import activity and questions about political responsibility and safeguards, with an editorial urging a broader, rule-of-law approach rather than letting headlines drive the response.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
